Who are ChondroCelect implantation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PCRA (Intermittent injection), Platelet Rich Plasma (PRP), Leukocyte rich platelet rich plasma, Low-dose PRP, Autologous platelets rich plasma, 3ml-Rejuvinex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chondrocelect-implantation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ChondroCelect implantation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ChondroCelect implantation (ChondroCelect implantation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy. Area: Orthopedics / Rheumatology.

phase 3 Autologous cell therapy Orthopedics / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

ChondroCelect implantation (ChondroCelect implantation) — TiGenix n.v.. ChondroCelect is an autologous cultured chondrocyte implant that replaces damaged cartilage by transplanting the patient's own expanded cartilage cells into the defect site.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
ChondroCelect implantation TARGET	ChondroCelect implantation	TiGenix n.v.	phase 3	Autologous cell therapy
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy class)

Tetec AG · 2 drugs in this class
GC Cell Corporation · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class
Sewon Cellontech Co., Ltd. · 1 drug in this class
StemCyte, Inc. · 1 drug in this class
TiGenix n.v. · 1 drug in this class
Cook MyoSite · 1 drug in this class
UnicoCell Biomed CO. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ChondroCelect implantation — Competitive Intelligence Brief. https://druglandscape.com/ci/chondrocelect-implantation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing